Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB phototherapy

Australasian Journal of Dermatology

Volumn 39, Issue 3, 1998, Pages 179-182

  Warren, Lachlan ^a   George, Shorn ^b  

^a AMERSHAM HOSPITAL   (United Kingdom)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE REPORT; ERYTHROPOIETIC PROTOPORPHYRIA; HUMAN; MALE; PHOTOTHERAPY; PRESCHOOL CHILD; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

EID: 0031857909     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-0960.1998.tb01278.x     Document Type: Article

References (24)

1. Magnus IA, Jarrett A, Prankcrd TAJ, Rimington C. Erythropoietic protoporphyria: A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 1961; ii: 448-51.
2. Todd DJ. Erytliropoietic protoporphyria. Br.J. Dermatol. 1994; 131: 751-G6.
3. Goerz G, Bunselmeyer S, Bolsen K, Schurer 1ST. Ferrochelatase activities in patients with erythropoietic protoporphyria and their families. Br. J. Dermatol. 199G; 134: 880-5.
4. Gouya L, Deybach JC, Lamoril J et al. Modulation of the phenotype in dominant crythropoietic protoporphyria by a low expression of thé normal ferrochelatase allele. Am. J. Hum. Genet. 1996; 58: 292-9.
5. Takelani S, Inazawa J, N'akahashi Y, Abc T, Tokunaga R. Structure of the human ferrochelatase gene. Exon/intron gene organisation and location of Üie gene to chromosome 18. Eur. J. Biochem. 1992; 205:217-22.
6. Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. I'liolodennalolog)-1985; 3: 148-57.
7. Lim HW, Gigli I, Wasserman SI. Differential effects of protoporphyrin and uroporphyrin on murine mast cells. J. Invest. Dermatol. 1987; 88: 281-6.
8. Varigos G, Schullz JR, Bickers DR. Uroporphyrin 1 stimulation of collagen biosynthesis in human skin fibroblasts. A unique direct dark effect of porphyrin. J. Clin. Invest. 1982; 09: 129-35.
9. Collins P, Fcrguson J. N'arrow-band (TL-01) phototherapy: An effective preventative treatment for the photodermatoses. Br. J. Dermatol. 1995; 132: 956-03.
10. Kaye ET, Levin JA, Blank III, Arndt KA, Rox Anderson R. Efficiency of opaque photoprotective agents in the visible light range. Arch. Demiatol. 1991; 127: 351-5.
11. Mathews-Roth MM, Pathak MA, Fitzpalrick TB, Harber LH, Kass EH. Beta carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch. Dennatol. 1977; 113: 1229-32.
12. Corbctt MF, Herxheimcr A, Magnus IA, Ramsay ÇA, Kobza-Black A. The long term treatment with beta-carotene in erythropoietic ' protoporphyria: A controlled trial. Br. J. Dcnnalol. 1977; 97: 655-2.
13. Zaynoun ST, Hunter JAA, Darby FJ, Zaremski P, Johnson BE, i Frain-BclI W. The treatment of erj'thropoietic protoporpliyria. Experience with beta-carotene. Br, J. Dennatol. 1977; 97: 663-8.
14. Mathews-Roth M. Carotenoids in erythropoietic protoporphyria and other photosensiitivity diseases. Ann. N. Y. Acad. Sci. 1993; 691 : 127-38.
15. Mathews-Roth MM, Rosncr B, Bcnfell K, Roberts JE. A double- : blind study of cystcine photoprotection in erythropoietic protoporphyria. Photodermalol. Photoimmunol. Pholomed. 1994; 10: 244-8.
16. Bijlmer-Iest JC, Baart de la Faille II, van Asbeck BS et al. I Protoporphyrin pliotosensitivity cannot be attenuated by oral ' A-acetylcysteine. Photodennatol. Photoimmunol. PlwtomciL 1992; 9: 245-9.
17. Norris PG, Baker CS, Roberts JE, Hawk JLM. Treatment ofcrythropoielic protopor])hyria with A-acetylcysteine. Arch. Dcnnalol. 1995; 151:354. '
18. Boffa MJ, Ead RD, Reed P, Weinkove C. A double-blind, placebo- , controlled, crossover trial of oral vitamin C in erythropoietic protoporphyria. Pholodennatol. Photoimmunol. Pholomed. 1996; 12: 27-30. i
19. Schoemaker JII, Bouseina MT, Zijlstra 11, van der Horst FAL. ' Treatment of erytliropoietic protoporphyria with hydroxyethylrutosides. Dennatolog)-1995; 191: 36-8.
20. Ros AM. PUVA therapy for erythropoietic protoporphyria. f Pholodcnnatolog)-1988; 5: 148-9.
21. Roelandts R. Photo (chemo)therapy and general management of . erythropoietic protoporphyria. Dennatolog)-1995; 190: 330-1. ,
22. Rademakcrs LH, Koningsberger JC, Sorber CW, de la Faille II, Van Hattum J, Marx JJ. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur. J. Clin. Invest. 1993; 23: 130-8.
23. Todd DJ, Burrows D. Predictable hazards of erythropoietic protoporphyria. Clin. Exp. Dennatol. 1992; 17: 141.
24. Todd DJ, Callender ME, Mayne EE, Walsh M, Burrows D. ' Erythropoietic protoporphyria, transfusion therapy and liver disease. Br. J. Dennatol. 1992; 127: 534-7. I